LabPulse.com

10/06/2023

Don't miss out on our free whitepaper resource: Conventional versus Convenience: Clinician Collected or At-Home Collected Testing for Sexually Transmitted Infections!

COVID-19 drove healthcare advancements in testing, treatment, and vaccines, notably mRNA technology. It heightened awareness of testing and its importance in daily life. In this whitepaper, we explore how to apply the lessons learned about infectious diseases during the pandemic to STIs.

Download the whitepaper here: https://bit.ly/48JIec0

08/03/2023

U.S. National Institutes of Health (NIH) has named Dr. Jeanne Marrazzo as Dr. Anthony Fauci’s full-time replacement as the head of the National Institute of Allergy and Infectious Diseases (NIAID).s://www.labpulse.com/business-insights/people-on-the-move/article/15543598/nih-names-jeanne-marrazzo-to-fill-niaid-post-vacated-by-anthony-fauci?utm_source=Facebook&utm_medium=Social&utm_campaign=Audience%20Development%20-%20SMGThe

Marrazzo currently works as director of the Division of Infectious Diseases at the University of Alabama at Birmingham and is expected to take up her position as the director of the NIAID in the fall.

07/26/2023

Molecular diagnostics company Co-Diagnostics is to receive over $2 million from the Bill & Melinda Gates Foundation toward completion of tuberculosis (TB) and human papillomavirus (HPV) tests for the company's Co-Dx PCR Home platform.

Dwight Egan, CEO of Co-Diagnostics, said the grants would help support the worldwide effort to prevent the spread of both TB and HPV in countries where they have been endemic killers for generations.

07/26/2023

Illumina has struck a deal to make Pillar Biosciences’ oncology assets commercially available globally as part of its own portfolio.

Pillar, which has partnerships with Beckman Coulter Life Sciences and Labcorp, designed its NSCLC and CRC panel to run on the Illumina MiSeq Dx instrument. The instrument is a next-generation sequencing (NGS) platform for in vitro diagnostic testing.

07/25/2023

Neuroscience is joining with two U.K. universities -- Bath and Bristol -- on the development of a test for cognition with potential as an early diagnosis tool in Alzheimer’s dementia.

The partnership will look to scale the development and testing of the Fastball EEG test, which uses an EEG headset to measure brain activity while patients watch a series of flashing images displayed on a tablet or smartphone screen.

07/24/2023

The U.S. Food and Drug Administration (FDA) has started a one-year pilot program to help reduce the risks associated with laboratory developed oncology tests.

The goal is to provide laboratories with information to support development of LDTs for specific cancer biomarkers, to facilitate “better and more consistent” testing and, by extension, “better drug selection and improved care for patients with cancer."

07/20/2023

The Association for Molecular Pathology (AMP) and other bodies have published recommendations on the inclusion of additional alleles in clinical pharmacogenomic (PGx) genotyping assays.

In its latest project, the working group investigated clinical CYP3A4 and CYP3A5 PGx testing, leading the AMP and its collaborators to issue consensus recommendations on the genes.

07/17/2023

An analysis of 462 million lipid test results has shown mean total cholesterol levels exceed the target in seven of the 17 studied countries.

Mean total cholesterol levels exceeded the World Health Organization (WHO) target in seven of the 17 countries included in the analysis, namely Japan, Australia, North Macedonia, Switzerland, Germany, Slovakia, and Austria.

07/14/2023

Whole genome sequencing (WGS) is better than a targeted test at identifying abnormalities responsible for genetic disorders in newborns and infants but also costs more and takes longer, according to a study published in JAMA.

WGS found a genetic disorder in 49% of the patients, compared to a 27% detection rate for NewbornDx. Overall, a molecular diagnostic variant was found in 51% of participants; 134 of the 297 identified variants were novel.

07/13/2023

Quest Diagnostics has launched its first consumer-initiated genetic test, Genetic Insights, which is available through its consumer site questhealth.com.

The test uses next-generation sequencing (NGS) technology to analyze thousands of DNA variants in the genes associated with the conditions within the test’s scope, searching more regions in the individual’s genome than microarray testing.

07/12/2023

Biosciences, a developer of noninvasive blood-based diagnostic tests for brain health and other diseases, has found a private partner specializing in automated machine learning (ML) to validate its biomarker panels and develop “highly accurate” diagnostic tests for Alzheimer’s disease and Rett syndrome, a genetic disease that affects brain development in girls.

Under the deal, DiamiR will apply the capabilities of JADBio’s Automated Machine Learning (AutoML) bioinformatics platform and services to its own microRNA platform.

07/12/2023

Through the analysis, the researchers identified 69 associations between CpGs and the prevalence of breast cancer, chronic kidney disease, ischemic heart disease, and type 2 diabetes. The majority of the associations had not previously been described.

11/22/2022

We wish you and yours a happy and festive Thanksgiving!

11/11/2022

This Veterans Day, we honor our servicemen and servicewomen for their bravery and sacrifice. Thank you for all you do.

10/24/2022

Welcome Stephen Wellman as Science and Medicine Group's first Director of Content Strategy. Read how Stephen plans to transform the user experience across all our media brands here: https://bit.ly/3TifjDz

03/08/2022

The FDA has resumed its review of laboratory-developed tests, rolling back a policy established under the Trump administration. The move is being praised in a new article published March 4 in JAMA.

The U.S. Food and Drug Administration (FDA) has resumed its review of laboratory-developed tests, rolling back a policy established under the Trump administration. The move is being praised in a new article published March 4 in JAMA.

02/28/2022

New research demonstrates that individuals who carry a genetic risk factor for severe COVID-19 infection also exhibit a 27% decreased chance of HIV infection compared to those who don't.

The major genetic risk factor for severe COVID-19 turns out to be something of a double-edged sword. New research demonstrates that individuals who carry the genetic variant also exhibit a 27% decreased chance of HIV infection compared to those who don't. The findings were published on February 21 i...